Acadia Pharmaceuticals ACAD Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Acadia Pharmaceuticals's total equity?
- Acadia Pharmaceuticals (ACAD) reported total equity of $1.25B in Q1 2026.
- How has Acadia Pharmaceuticals's total equity changed year-over-year?
- Acadia Pharmaceuticals's total equity increased by 63.1% year-over-year, from $765.24M to $1.25B.
- What is the long-term trend for Acadia Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), Acadia Pharmaceuticals's total equity has grown at a 14.4% compound annual growth rate (CAGR), from $627.01M to $1.23B.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.